2026-01-04 - Analysis Report
Okay, here's a breakdown of the Recursion Pharmaceuticals (RXRX) stock data, including analysis and a summary:

**1) Return Rate Comparison**

*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to discover and develop drugs.
*   **RXRX Cumulative Return:** -31.43%
*   **VOO (S&P 500) Cumulative Return:** 39.85%
*   **Divergence:** Current: -74.0, Relative Divergence: 0.7

**Analysis:** RXRX has significantly underperformed the S&P 500 over the given period. The divergence of -74.0 indicates a substantial difference in returns. The relative divergence of 0.7 suggests it's only slightly out of its worst recent performance divergence compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2022-2024  | 11.0% | 55.8% | -9.0%  | 2.3  | 3.5    |
| 2023-2025  | 9.0%  | 59.2% | -53.0% | 2.6  | 2.1    |

*   **CAGR (Compound Annual Growth Rate):** Shows decent growth over both periods, but it's decreasing.
*   **MDD (Maximum Drawdown):** Very high, indicating substantial risk.
*   **Alpha:** Significantly negative, particularly in the 2023-2025 period, meaning the stock has underperformed relative to its risk.
*   **Beta:** High (above 1), indicating the stock is more volatile than the market.
*   **Cap(B) (Capitalization in Billions):** Decreasing, suggesting a decline in the company's market value.

**Overall Alpha/Beta analysis Interpretation:** The stock is high-risk (high Beta, high MDD) and has significantly underperformed expectations given that risk (negative Alpha).

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 4.20
*   **Last Market Data:** Price: 4.20, Previous Close: 4.09, Change: 2.69%
*   **5-day SMA:** 4.156
*   **20-day SMA:** 4.431
*   **60-day SMA:** 4.9053

**Analysis:** The stock price closed slightly up (2.69% change). The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA. This indicates a short-term upward trend, but a longer-term downward trend.

**3) Indicator Analysis**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment)
*   **RSI (Relative Strength Index):** 40.10 (Not overbought or oversold)
*   **PPO (Percentage Price Oscillator):** -0.3699 (Slightly bearish, indicating the short-term moving average is below the long-term)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (228 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.7 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -534.2 (Very poor expected return compared to S&P 500 if invested long-term.)

**Analysis:** The MRI suggests a medium level of investment risk, but the very negative expected return is a major red flag. The Hybrid Signal's recommendation should be viewed cautiously given the other negative indicators.  The recent increase in relative divergence suggests a possible short-term bounce, but the overall outlook is concerning.

**4) Recent News & Significant Events**

*   **Mixed Headlines:** The news headlines present a mixed picture:
    *   Some articles touting potential (Yahoo Finance "Best Penny Stock", Forbes "JPMorgan Upgrade", Seeking Alpha "JPMorgan upgrade")
    *   Others reporting negative performance (Quiver Quantitative "fell 9% this week", timothysykes.com "Stock Plummet")
    *   Nikko Asset Management selling shares suggests institutional selling pressure (MarketBeat)

**Analysis:** The news sentiment is highly varied. The JP Morgan upgrade provides some positive momentum, but the negative performance reports and share selling highlight underlying challenges. A careful assessment of the reasons behind the upgrade is necessary.

**4-2) Analyst Opinions**

*   **Consensus:** No Key, Mean rating unavailable.
*   **Opinions:** 7 analysts
*   **Target Price:** Avg: $7.00, High: $11.00, Low: $3.00
*   **Recent Rating Changes:** Not Available

**Analysis:** The analyst target price range is very wide, indicating a high degree of uncertainty about the stock's future performance. The average target price is significantly higher than the current price, suggesting potential upside, but the lack of recent rating changes makes it hard to confirm how recent those are.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-05 | -0.36 | 0.01 B$    |
| 2025-08-05 | -0.41 | 0.02 B$    |
| 2025-05-05 | -0.5  | 0.01 B$    |
| 2024-11-06 | -0.34 | 0.03 B$    |
| 2025-11-05 | -0.34 | 0.03 B$    |

**Analysis:** Earnings per share (EPS) are consistently negative and have generally worsened recently. Revenue is low and volatile. This points to significant challenges in achieving profitability.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.00B  | -194.74%      |
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE    |
|------------|---------|--------|
| 2025-09-30 | $1.05B  | -15.50% |
| 2025-06-30 | $0.92B  | -18.70% |
| 2025-03-31 | $0.93B  | -21.68% |
| 2024-12-31 | $1.03B  | -17.29% |
| 2024-09-30 | $0.52B  | -18.27% |

**Analysis:** Revenue is very low and inconsistent, and profit margins are overwhelmingly negative, indicating significant losses. While equity remains relatively stable, the Return on Equity (ROE) is consistently negative, demonstrating the company's inability to generate profits from shareholder investments.

**7) Comprehensive Analysis (Summary)**

*   **Poor Performance:** RXRX has significantly underperformed the S&P 500, with a large negative divergence.
*   **High Risk:** Alpha/Beta analysis indicates high volatility and significant underperformance relative to the risk taken.
*   **Uncertain Outlook:** The recent stock price fluctuations show a short-term upward trend but a longer-term downward trend. The MRI indicates medium risk, but the very negative expected return is a concern.
*   **Mixed Sentiment:** News headlines and analyst opinions are mixed, making it difficult to assess the stock's future prospects. While some analysts have provided upgrades, there are also reports of negative performance and share selling.
*   **Financial Challenges:** The company faces significant financial challenges, with consistently negative EPS, low and inconsistent revenue, negative profit margins, and negative ROE.

**Conclusion:**

Based on the data provided, Recursion Pharmaceuticals appears to be a high-risk investment with significant financial challenges. While there may be short-term opportunities due to news events or analyst upgrades, the overall outlook is concerning. Further research and a thorough understanding of the company's strategy and competitive landscape are necessary before considering an investment. The exceptionally low expected return suggests extreme caution.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.